ÂÜÀòÂÒÂ×

Daniel Wagner is an accomplished investment professional with extensive experience in the biotechnology sector. Currently serving as the Senior Managing Director of Investments at Connecticut Innovations since November 2007, Daniel has held various roles within the organization including Managing Director and Director of Investments. In addition to responsibilities at Connecticut Innovations, Daniel acts as a Board Observer for multiple companies including RIGImmune Inc., Alphina Therapeutics, and Simcha Therapeutics, among others. Daniel's prior board membership at P2 Science, Inc. and current tenure at Tangen Biosciences, Inc. further underscore a strong commitment to nurturing innovative ventures. Educational qualifications include an MBA in Finance from Quinnipiac University and a degree in Biomedical Sciences from the same institution, complemented by a Bachelor of Science in Biology from the University of Dayton. Daniel also completed training at the Venture Capital Institute in 2008.